BIOTECHNOLOGY SYSTEMS BRANCH



RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/841,091
Source: OIPE
Date Processed by STIC: 12/20/2001

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:
1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY
FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.
PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)
PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO **REDUCE** ERRORED SEQUENCE LISTINGS, **PLEASE** USE THE **CHECKER VERSION 3.1 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:
http://www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by the treatment given to all mail coming via the Brentwood Mail Facility.
Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom, including:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>, **EFS Submission User Manual** - ePAVE)
2. U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
   U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, 1911 South Clark Street, Crystal Mall One, Sequence Information, Arlington, VA 22202
   Or
   U.S. Patent and Trademark Office, 2011 South Clark Place, Customer Window, Box Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, Virginia 22202
4. Federal Express Delivery, 2011 South Clark Street, Crystal Plaza 2, Room 1B03-Mailroom, Box Sequence, Arlington, VA 22202

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/841,091

DATE: 12/20/2001
TIME: 21:07:02

Input Set : A:\NEMC-215.txt
Output Set: N:\CRF3\12202001\I841091.raw

Does Not Comply
Corrected Diskette Needed

<110> APPLICANT: Kuliopulos, Athan
Covic, Lidija

<120> TITLE OF INVENTION: G Protein Coupled Receptor (GPCR) Agonists and Antagonists and Methods of Activating and Inibiting GPCR Using the Same

<130> FILE REFERENCE: 18475-034

<140> CURRENT APPLICATION NUMBER: 09/841,091

<141> CURRENT FILING DATE: 2001-04-23

<150> PRIOR APPLICATION NUMBER: 60/198,993

<151> PRIOR FILING DATE: 2000-04-21

<160> NUMBER OF SEQ ID NOS: 37

<170> SOFTWARE: PatentIn Ver. 2.1

<210> SEQ ID NO: 1

<211> LENGTH: 19

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin Peptide Sequence

<400> SEQUENCE: 1

Arg Cys Leu Ser Ser Ser Ala Val Ala Asn Arg Ser Lys Lys Ser Arg
1 5 10 15

Ala Leu Phe

<210> SEQ ID NO: 2

<211> LENGTH: 13

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin Peptide Sequence

<400> SEQUENCE: 2

Ala Val Ala Asn Arg Ser Lys Lys Ser Arg Ala Leu Phe
1 5 10

<210> SEQ ID NO: 3

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin Peptide Sequence

<400> SEQUENCE: 3

Lys Lys Ser Arg Ala Leu Phe
1 5

<210> SEQ ID NO: 4

<211> LENGTH: 12

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

RAW SEQUENCE LISTING DATE: 12/20/2001
PATENT APPLICATION: US/09/841,091 TIME: 21:07:02

Input Set : A:\NEMC-215.txt
Output Set: N:\CRF3\12202001\I841091.raw

<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin
Peptide Sequence
<400> SEQUENCE: 4
Arg Cys Leu Ser Ser Ser Ala Val Ala Asn Arg Ser
1 5 10
<210> SEQ ID NO: 5
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin
Peptide Sequence
<400> SEQUENCE: 5
Arg Cys Leu Ser Ser Ser Ala Val Ala Asn Ser Ser Ala Leu Phe
1 5 10 15
<210> SEQ ID NO: 6
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin
Peptide Sequence
<400> SEQUENCE: 6
Arg Cys Glu Ser Ser Ser Ala Glu Ala Asn Arg Ser Lys Lys Glu Arg
1 5 10 15
Glu Leu Phe
<210> SEQ ID NO: 7
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin
Peptide Sequence
<400> SEQUENCE: 7
Arg Met Leu Arg Ser Ser Ala Met Asp Glu Asn Ser Glu Lys Lys Arg
1 5 10 15
Lys Arg Ala Ile Lys
20
<210> SEQ ID NO: 8
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin
Peptide Sequence
<400> SEQUENCE: 8
Arg Met Leu Arg Ser Ser Ala Met Asp Glu Asn Ser Glu Lys Lys Arg
1 5 10 15

RAW SEQUENCE LISTING DATE: 12/20/2001
PATENT APPLICATION: US/09/841,091 TIME: 21:07:02

Input Set : A:\NEMC-215.txt
Output Set: N:\CRF3\12202001\I841091.raw

```
Lys Arg Ala Ile Phe
            20
<210> SEQ ID NO: 9
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin
      Peptide Sequence
<400> SEQUENCE: 9
His Thr Leu Ala Ala Ser Gly Arg Arg Tyr Gly His Ala Leu Arg
  1               5                  10                  15
<210> SEQ ID NO: 10
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin
      Peptide Sequence
<400> SEQUENCE: 10
His Thr Leu Ala Ala Ser Gly Arg Arg Tyr Gly His Ala Leu Phe
  1               5                  10                  15
<210> SEQ ID NO: 11
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin
      Peptide Sequence
<400> SEQUENCE: 11
Lys Val Lys Ser Ser Gly Ile Arg Val Gly Ser Ser Lys Arg Lys Lys
  1               5                  10                  15
Ser Glu Lys Lys Val Thr Lys
            20
<210> SEQ ID NO: 12
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin
      Peptide Sequence
<400> SEQUENCE: 12
Lys Val Arg Ser Ser Gly Ile Arg Val Gly Ser Ser Lys Arg Lys Lys
  1               5                  10                  15
Ser Glu Lys Lys Val Thr Phe
            20
<210> SEQ ID NO: 13
<211> LENGTH: 19
<212> TYPE: PRT
```

RAW SEQUENCE LISTING DATE: 12/20/2001
PATENT APPLICATION: US/09/841,091 TIME: 21:07:02

Input Set : A:\NEMC-215.txt
Output Set: N:\CRF3\12202001\I841091.raw

211 <213> ORGANISM: Artificial Sequence
213 <220> FEATURE:
214 <223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin
215 Peptide Sequence
217 <400> SEQUENCE: 13
218 Arg Ile Arg Ser Asn Ser Ser Ala Ala Asn Leu Met Ala Lys Lys Arg
219 1 5 10 15
221 Val Ile Arg
225 <210> SEQ ID NO: 14
226 <211> LENGTH: 20
227 <212> TYPE: PRT
228 <213> ORGANISM: Artificial Sequence
230 <220> FEATURE:
231 <223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin
232 Peptide Sequence
234 <400> SEQUENCE: 14
235 Arg Ile Arg Ser Asn Ser Ser Ala Ala Asn Leu Met Ala Lys Lys Arg
236 1 5 10 15
238 Val Ile Glu Phe
239 20
242 <210> SEQ ID NO: 15
243 <211> LENGTH: 18
244 <212> TYPE: PRT
245 <213> ORGANISM: Artificial Sequence
247 <220> FEATURE:
248 <223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin
249 Peptide Sequence
251 <400> SEQUENCE: 15
252 Ser Gly Ser Arg Pro Thr Gln Ala Lys Leu Leu Ala Lys Lys Arg Val
253 1 5 10 15
255 Val Arg
259 <210> SEQ ID NO: 16
260 <211> LENGTH: 18
261 <212> TYPE: PRT
262 <213> ORGANISM: Artificial Sequence
264 <220> FEATURE:
265 <223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin
266 Peptide Sequence
268 <400> SEQUENCE: 16
269 Ser Gly Ser Arg Pro Thr Gln Ala Lys Leu Leu Ala Lys Lys Arg Val
270 1 5 10 15
272 Val Phe
276 <210> SEQ ID NO: 17
277 <211> LENGTH: 6
278 <212> TYPE: PRT
279 <213> ORGANISM: Artificial Sequence
281 <220> FEATURE:
282 <223> OTHER INFORMATION: Description of Artificial Sequence: Extracellular
283 Agonist Peptide Sequence

RAW SEQUENCE LISTING DATE: 12/20/2001
PATENT APPLICATION: US/09/841,091 TIME: 21:07:02

Input Set : A:\NEMC-215.txt
Output Set: N:\CRF3\12202001\I841091.raw

```
285 <400> SEQUENCE: 17
286 Ser Leu Ile Gly Lys Val
287   1               5
290 <210> SEQ ID NO: 18
291 <211> LENGTH: 14
292 <212> TYPE: PRT
293 <213> ORGANISM: Artificial Sequence
295 <220> FEATURE:
296 <223> OTHER INFORMATION: Description of Artificial Sequence: Extracellular
297       Agonist Peptide Sequence
299 <400> SEQUENCE: 18
300 Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
301   1               5                  10
304 <210> SEQ ID NO: 19
305 <211> LENGTH: 97
306 <212> TYPE: PRT
307 <213> ORGANISM: Artificial Sequence
309 <220> FEATURE:
310 <223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin
311       Peptide Sequence
313 <220> FEATURE:
314 <221> NAME/KEY: VARIANT
315 <222> LOCATION: (1)..(97)
316 <223> OTHER INFORMATION: Wherein Xaa is a space/gap induced by peptide
317       alignment analysis
319 <400> SEQUENCE: 19
W--> 320 Arg Cys Leu Ser Ser Ser Ala Val Ala Asn Arg Ser Xaa Xaa Xaa Xaa
321   1               5                  10                  15
W--> 323 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
324             20                  25                  30
W--> 326 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
327         35                  40                  45
W--> 329 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
330     50                  55                  60
W--> 332 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
333  65                  70                  75                  80
W--> 335 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys Lys Ser Arg Ala Leu
336                 85                  90                  95
338 Phe
342 <210> SEQ ID NO: 20
343 <211> LENGTH: 97
344 <212> TYPE: PRT
345 <213> ORGANISM: Artificial Sequence
347 <220> FEATURE:
348 <223> OTHER INFORMATION: Description of Artificial Sequence: Pepducin
349       Peptide Sequence
351 <220> FEATURE:
352 <221> NAME/KEY: VARIANT
353 <222> LOCATION: (1)..(97)
```

Xaa can only represent a single amino acid.

Per 1.822(5)(e) of Sequence Rules, "A sequence with a gap or gaps shall be presented as a plurality of separate sequences, with separate sequence identifiers ..."

Use of n and/or Xaa has been detected in the Sequence Listing. Review the Sequence Listing to insure a corresponding explanation is presented in the <220> to <223> fields of each sequence using n or Xaa.

VERIFICATION SUMMARY DATE: 12/20/2001
PATENT APPLICATION: US/09/841,091 TIME: 21:07:03

Input Set : A:\NEMC-215.txt
Output Set: N:\CRF3\12202001\I841091.raw

L:320 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19
L:323 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19
L:326 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19
L:329 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19
L:332 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19
L:335 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19
L:358 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
L:361 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
L:364 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
L:367 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
L:370 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
L:373 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
L:402 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:21
L:408 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:21
L:411 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:21
L:434 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:437 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:466 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:469 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:472 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:475 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:478 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:481 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:504 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24
L:507 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24
L:510 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24
L:513 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24
L:516 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24
L:542 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25
L:545 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25
L:548 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25
L:551 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25
L:554 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25
L:557 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25
L:580 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:26
L:603 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:27
L:626 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:28
L:649 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:29
L:669 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:30
L:692 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31